Daily MaverickTHE CONVERSATION: Why eating a handful of nuts daily might lower risk of high blood pressureInquirerNCRPO warns Asean rallyists: Assaulting cops may lead to rapsThe Jerusalem PostEuropean militaries hunt for homegrown AI alternatives to cut reliance on US giant PalantirZDF heuteAktuelle Pressemitteilungen des ZDFStraits Times SportWoods to make competitive return at December's Hero World ChallengeSCMP ChinaTrump eyes China after brief Manila stop, seeking chemistry with Xi amid fresh AI strainsIl Fatto Quotidiano“Mi è stata diagnosticata una malattia coronarica, l’ho scoperto con un test di 3 minuti. La mia peggiore paura, si avvera”: parla Gio Benitez di Good Morning America20 MinutenRoche erhält erste US-Zulassung für Brustkrebs-MedikamentWirtualna PolskaTusk ostro o wotum nieufności wobec rządu. "Hucpa"The South AfricanWEATHER TOMORROW: Thunderstorms threaten Free State as heat grips Western Capen-tvHarte Nuss für Samsung: Xiaomi 18 Pro greift mit zwei Displays und Riesen-Akku anVanguardUS House committees to quiz Nvidia ex-CEO Huang December 1
The Daily Newsstand · Free, Always
Tuesday, November 17, 2026

Science Corporation’s brain tech is worth $3.5 billion after new funding

Translate
Image Credits:Kimberly White/Getty Images for TechCrunch
  • Tim Fernholz

Science Corporation, the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post.

Investors in the new round valued the company at $3.5 billion, a person familiar with the deal told TechCrunch. Those backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

Hodak, who talked his way into a graduate neuroscience lab as a college student and has pursued biotechnology ever since, co-founded Science to leverage new technologies to understand and interact with the brain.

Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, as well as being trialled for new conditions.

Hodak announced that the device is now being trialled for patients with another blindness-causing condition, Stargardt’s disease, while onstage at TechCrunch Disrupt.

With the funding, the company aims to bring the device to the United States through the FDA’s Humanitarian Device Exemption, which lets experimental medical technology be used to treat rare conditions. Science has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to let them seek approval to use the device on people in the US.

Still, the startup’s big ambition and founding purpose is connecting directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. The company is currently designing initial human trials of the device with Yale neurosurgery professor Murat Günel, who told TechCrunch it could offer potential treatments for Parkinson’s disease, among other brain injuries and illnesses.

View the original on TechCrunch →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.